The use and utility of toolkits in supporting cabotegravir plus rilpivirine long-acting implementation in the CARISEL (Cabotegravir And Rilpivirine Implementation Study in European Locations) study

被引：0

作者：

Trehan, Rekha ^{[1
]}

Gutner, Cassidy ^{[2
]}

Okoli, Chinyere ^{[1
]}

Ghosn, Jade ^{[3
]}

Vera, Francisco ^{[4
]}

Florence, Eric ^{[5
]}

Lutz, Thomas ^{[6
]}

van der Valk, Marc ^{[7
,8
]}

Czarnogorski, Maggie ^{[2
]}

机构：

[1] ViiV Healthcare, Brentford, England

[2] ViiV Healthcare, Durham, NC USA

[3] Univ Paris, Paris, France

[4] Hosp Gen Univ Santa Lucia, Murcia, Spain

[5] Inst Trop Geneeskunde, Antwerp, Belgium

[6] Infekt Res, Frankfurt, Germany

[7] Univ Amsterdam, Amsterdam, Netherlands

[8] Amsterdam Inst Infect & Immun, Amsterdam, Netherlands

来源：

HIV MEDICINE | 2023年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

P111

引用

页码：93 / 93

页数：1

共 50 条

[41] Initiation of cabotegravir and rilpivirine long-acting (CAB plus RPV LA) regimen across five European countries in CARISEL during the COVID-19 pandemic
Czarnogorski, Maggie
Wang, Yongwei
Tomkins, Ms. Susan
Yu, Ren
Barnes, Nicola
Patel, Parul
Gill, Martin
Ait-Khaled, Mounir
Gutner, Cassidy
Moorhouse, Michelle
D'Amico, Ronald
Bosse, Matthew
HIV MEDICINE, 2021, 22 : 5 - 6
[42] Weight and body mass index changes in women receiving cabotegravir plus rilpivirine long-acting or bictegravir in the SOLAR study
Patel, Parul
Elliot, Emilie
Zhang, Feifan
Urbaityte, Rimgaile
Sutherland-Phillips, Denise
Sutton, Kenneth
Walmsley, Sharon
D'Amico, Ronald
Spreen, William
Baugh, Bryan
van Wyk, Jean
HIV MEDICINE, 2023, 24 : 56 - 56
[43] Long-Acting Cabotegravir/Rilpivirine Concentrations in Combination With Intravenous Rifampin: A Case Report
Sunagawa, Shawnalyn W.
Havens, Joshua P.
Podany, Anthony
Walker, Bryan
Scarsi, Kimberly K.
Bares, Sara H.
OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (12):
[44] Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine
Mazzitelli, Maria
Avolio, Antonio
Carandina, Riccardo
Parisi, Saverio
Wensing, Annemarie
Cattelan, Annamaria
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (08) : 2074 - 2076
[45] In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents
Rajith K. R. Rajoli
David J. Back
Steve Rannard
Caren Freel Meyers
Charles Flexner
Andrew Owen
Marco Siccardi
Clinical Pharmacokinetics, 2018, 57 : 255 - 266
[46] In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents
Rajoli, Rajith K. R.
Back, David J.
Rannard, Steve
Meyers, Caren Freel
Flexner, Charles
Owen, Andrew
Siccardi, Marco
CLINICAL PHARMACOKINETICS, 2018, 57 (02) : 255 - 266
[47] Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and Rilpivirine
Pintado, Claire
Delaugerre, Constance
Molina, Jean-Michel
OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (09):
[48] Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
Hodge, Daryl
Back, David J.
Gibbons, Sara
Khoo, Saye H.
Marzolini, Catia
CLINICAL PHARMACOKINETICS, 2021, 60 (07) : 835 - 853
[49] Long-acting cabotegravir and rilpivirine plasma exposures in the clinical setting: The role of pharmacogenetics
Cusato, Jessica
Ferrara, Micol
Antonucci, Miriam
Goldan, Razvan
Soloperto, Sara
Di Perri, Giovanni
D'avolio, Antonio
Calcagno, Andrea
Bonora, Stefano
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 : 11 - 11
[50] WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIALS
Patel, P.
D'Amico, R.
Thiagarajah, S.
Wu, S.
Elliot, E.
Polli, J. W.
Upadhyay, O.
Van Solingen-Ristea, R.
Orkin, C.
Overton, E. T.
Swindells, S.
van Wyk, J.
Bosse, M.
Vannappagari, V.
Gray, L.
SEXUAL HEALTH, 2021, 18 (04) : VI - VI

← 1 2 3 4 5 →